- Conditions
- Coronary Heart Disease, Metabolic Syndrome, Diabetes Mellitus
- Interventions
- PET scan, Echocardiogram
- Radiation
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1417–1440
of 2,323
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Sclerosis
- Interventions
- [18F]Florbetapir PET imaging
- Drug
- Lead sponsor
- Institute for Neurodegenerative Disorders
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Clear Cell Renal Cell Carcinoma, Kidney Cancer, Advanced Renal Cell Carcinoma
- Interventions
- 177Lu-labeled-girentuximab, Nivolumab, 89Zr-girentuximab PET/CT, 177Lu whole body (WB) planar and SPECT/CT scans
- Drug · Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1
- Interventions
- [203Pb]VMT-α-NET, SPECT/CT
- Drug · Device
- Lead sponsor
- Yusuf Menda
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone
- Interventions
- Biospecimen Collection, Bone Scan, Computed Tomography, Electronic Health Record Review, Magnetic Resonance Imaging, Paclitaxel, Radium Ra 223 Dichloride, Single Photon Emission Computed Tomography
- Procedure · Other · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Duarte, California • Orange, California + 26 more
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Antiandrogen Therapy, Bone Scan, Computed Tomography, Cytotoxic Chemotherapy, FDG-Positron Emission Tomography, Radiation Therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • DeKalb, Illinois • Geneva, Illinois + 3 more
- Conditions
- Cardiac
- Interventions
- Not listed
- Lead sponsor
- State University of New York - Upstate Medical University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2011
- U.S. locations
- 1
- States / cities
- Syracuse, New York
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- Ketamine hydrochloride infusion
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- High-grade Glioma, Lung Cancer, Head & Neck Cancer, Sarcoma, Melanoma
- Interventions
- Fluciclatide Injection - (AH111585 (F18))
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Head and Neck Cancer
- Interventions
- intensity modulated radiation therapy, RAD001 (everolimus) + Cisplatin
- Radiation · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, Echocardiography Test, HER2-targeted Therapy, Hormone Therapy, Magnetic Resonance Imaging, Mammography, Pertuzumab, Positron Emission Tomography, Radiation Boost, Radiation Therapy, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Taxane Compound, Total Mastectomy, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine, Ultrasound Imaging
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 562 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2033
- U.S. locations
- 59
- States / cities
- Jonesboro, Arkansas • Derby, Connecticut • Fairfield, Connecticut + 45 more
- Conditions
- Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Busulfan, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, External Beam Radiation Therapy, Iobenguane I-123, Iobenguane I-131, Isotretinoin, Lorlatinib, Magnetic Resonance Imaging, Melphalan Hydrochloride, Multigated Acquisition Scan, Positron Emission Tomography, Sargramostim, Therapeutic Conventional Surgery, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 365 Days to 30 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 152
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 121 more
- Conditions
- Tauopathies
- Interventions
- 11C-HY-2-15 PET, brain MRI, Amyloid PET scan, Neurological assessments
- Drug · Diagnostic Test · Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, EGFRt/19-28z/IL-12 CAR T-lymphocytes, Fludarabine Phosphate, Leukapheresis, Multigated Acquisition Scan, Positron Emission Tomography
- Procedure · Drug · Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Rituximab, Venetoclax
- Procedure · Biological · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- EGFR Gene Amplification, EGFR Gene Mutation, Glioblastoma, Recurrent Glioblastoma, Supratentorial Glioblastoma, TP53 Wt Allele
- Interventions
- Fludeoxyglucose F-18, Osimertinib, Positron Emission Tomography
- Other · Drug · Procedure
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Alcoholism
- Interventions
- [11C]flumazenil, Tiagabine
- Radiation · Drug
- Lead sponsor
- Rajesh Narendran
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Malignant Neoplasm in the Spine
- Interventions
- Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
- Procedure · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Aging, Cognitive Ability, General
- Interventions
- Moderate-aerobic walking, Positron Emission Tomography (PET) scan, Healthy living education, Physical activity monitor
- Behavioral · Radiation · Device
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Healthy
- Interventions
- Hydrocortisone, [C-11]NOP-1A
- Drug · Radiation
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Metastic Thyroid Cancer
- Interventions
- 68-Gallium-DOTATATE-PET/CT
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 98 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diagnostic Imaging
- Interventions
- BAY1075553
- Drug
- Lead sponsor
- Lantheus Biosciences Ltd.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Heart Disease
- Interventions
- SPECT imaging, PET imaging
- Other
- Lead sponsor
- Hartford Hospital
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 5
- States / cities
- Huntsville, Alabama • Hartford, Connecticut • Kansas City, Missouri + 2 more
- Conditions
- PostTraumatic Stress Disorder
- Interventions
- GammaCore/electroCore non-invasive VNS device, Sham gammaCore/electroCore, O-15 water
- Device · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia